Experimental infections of monkeys with lymphotropic SIV strains have indicated that the production of protective immune responses to SIV requires a lengthy and complex maturation of humoral and cellular immune responses. However, little in known about the specificity of these protective immune responses, thus hindering the design of effective vaccine strategies. This NCVDG has recently discovered that inoculation of macaques with attenuated macrophage tropic SIV17E/C1 resulted in a rapid evolution of broadly protective immunity to experimental SIV challenge. These observations suggest that attenuated macrophage tropic SIV vaccines provide a unique model to examine the maturation and specificity of protective immune responses to SIV. This project is designed to characterize the evolution of antibody responses mediating broad protection against SIV and to determine the specificity of the SIV antigenic determinants that elicit these protective immune responses in macaques in monkeys immunized with attenuated SIV vaccines and in monkeys that are long term survivors of infection with pathogenic strains of SIV. The following specific aims are proposed to achieve these objectives: (1) to map conformational and linear antigenic determinants of SIV envelope glycoproteins using rhesus monoclonal and polyclonal antibodies, (2) to determine the specificity of protective antibodies produced in immunized monkeys by analyses of immune serum antibodies fractionated according to their antigenic determinants on SIV envelope proteins, (3) to characterize the evolution of protective antibodies by monitoring critical antibody properties, and (4) to extend these studies with SIV to the SHIV chimeric virus model. It is anticipated that the results of these studies of antibody responses to SIV will provide fundamental new information on SIV envelope protein immunogenicity, elucidate the specificity of protective antibody responses to SIV, and establish critical immune correlates of protection that can be used as performance standards and as prognostic in vitro indicators for evaluating vaccine efficacy in vivo.

Project Start
1999-04-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Steckbeck, J D; Grieser, H J; Sturgeon, T et al. (2006) Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol 35:248-60
Sarkar, Surojit; Kalia, Vandana; Murphey-Corb, Michael et al. (2003) Expression of IFN-gamma induced CXCR3 agonist chemokines and compartmentalization of CXCR3+ cells in the periphery and lymph nodes of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. J Med Primatol 32:247-64
Sarkar, Surojit; Kalia, Vandana; Montelaro, Ronald C (2003) Caspase-mediated apoptosis and cell death of rhesus macaque CD4+ T-cells due to cryopreservation of peripheral blood mononuclear cells can be rescued by cytokine treatment after thawing. Cryobiology 47:44-58
Sarkar, Surojit; Kalia, Vandana; Murphey-Corb, Michael et al. (2002) Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope. J Immunol 168:4001-11
Sarkar, S; Kalia, V; Murphey-Corb, M et al. (2002) Characterization of CD4+ T helper cell fine specificity to the envelope glycoproteins of simian immunodeficiency virus. J Med Primatol 31:194-204
Seman, A L; Pewen, W F; Fresh, L F et al. (2000) The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol 81:2441-9
Cole, K S; Murphey-Corb, M; Narayan, O et al. (1998) Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol 72:7852-9